Dr. Reddy's Laboratories Limited

NYSE:RDY

Drug Manufacturers - Specialty & Generic

Healthcare
$14.98 -1.13%

-$0.15 today

Market cap
$12.48B
Beta
0.26
P/E (TTM)
24.7
EPS (TTM)
$51.40
Dividend yield
0.63%
52W Low $12.19High $15.71

Volume 1.79M

Average 2.39M

RDY Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Dr. Reddy's Laboratories LimitedNYSE: RDY

Selling, General & Admin · Q2 FY2027 · quarter ended Sep 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q2 FY2027 selling, general & admin of ₹28.04B rose 6.1% year over year, behind the +14.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at +18.2% a year.

Context

  • Selling, general & admin amounted to 31.8% of revenue in FY2026, up 2.9 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 18 analysts of ₹102.97B (-8.3%) for the fiscal year ending Mar 2027, a slowdown from the +19.7% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
₹28.04B-3.3% QoQ
Last fiscal yearMar 2026
₹112.34B+19.7% YoY
LTMSep 2026
₹112.14B+14.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.1%-1.3%-7.3 pp
1 year+19.7%-8.3%-28.0 pp
3-year CAGR+18.2%+4.3%-13.9 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

INR · from the income statement

Latest · FY2026
112.34B INR
Year-over-year change
+19.7%
4-year CAGR
+16.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How RDY compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.7% is the 3rd highest of 7, against a peer median of +11.6%.
  • Selling, general & admin amounts to 33.8% of revenue for RDY, versus a peer median of 27.0%.
RDY Competitors
Selling, General & Admin for RDY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹112.14B INR+14.7%+18.2%33.8%
HLNHaleon plcLTM Jun 2025£6.42B GBP—+2.6%38.8%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$4.13B USD+9.9%+4.9%23.8%
VTRSViatris Inc.LTM Jun 2026$3.98B USD+1.3%-3.2%27.0%
BHCBausch Health Companies Inc.LTM Jun 2026$3.45B USD+0.5%+10.7%31.7%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$571.86M USD+16.7%+9.6%18.3%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$314.87M USD+13.2%+36.8%34.1%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$131.9M USD+35.5%+24.9%18.3%
Peer median (excluding RDY) —+11.6%+9.6%27.0%

Competitors are the stored peer set for RDY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

INR
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue214.39B245.88B279.16B325.54B353.47B
Cost of Revenue100.55B106.54B115.56B135.11B166.95B
Gross Profit113.84B139.34B163.61B190.43B186.52B
Gross Margin53.1%56.7%58.6%58.5%52.8%
Research & Development17.48B19.38B22.87B27.38B25.31B
Selling, General & Admin62.08B68.03B77.2B93.87B112.34B
Operating Expenses84.36B82.2B95.88B118.59B137.65B
Depreciation & Amortization11.82B12.64B14.84B17.06B21.68B
EBITDA45.08B74.43B88.42B96.67B83.29B
EBITDA Margin21.0%30.3%31.7%29.7%23.6%
Operating Income29.48B57.14B67.73B71.84B48.87B
Operating Margin13.7%23.2%24.3%22.1%13.8%
Interest Income965M1.18B2.28B2.68B8.28B
Interest Expense958M1.43B1.71B2.83B3.93B
Other Income / Expenses2.82B3.22B4.14B4.94B8.81B
Income Before Tax32.3B60.37B71.87B76.78B57.68B
Pre-Tax Margin15.1%24.6%25.7%23.6%16.3%
Income Tax Expense8.73B15.3B16.19B19.54B13B
Net Income23.57B45.07B55.68B56.54B45.09B
Net Margin11.0%18.3%19.9%17.4%12.8%
EPS (Basic)28.4254.2966.8067.8553.92
EPS (Diluted)28.3454.1766.8067.7753.92
Weighted Avg Shares829.41M830.17M833.54M833.31M832.41M
Weighted Avg Shares (Diluted)831.69M831.91M833.54M834.3M833.26M

Dr. Reddy's Laboratories Limited

NYSE:RDY

Intrinsic Alpha fair value

Locked

Current Price

$14.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.